CLINICAL TRIALS PROFILE FOR TRIHEPTANOIN
✉ Email this page to a colleague
All Clinical Trials for triheptanoin
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00328159 ↗ | Nutritional Therapy of the Deficits of Oxidation Mitochondrial of the Fatty Acids | Completed | Assistance Publique - Hôpitaux de Paris | N/A | 2006-06-01 | Usual dietary therapies of mitochondrial fatty acid oxidation disorders (FAO) are based on 3 strategies: - limitation of lipid intake in the diet; - supplementation of the diet with medium-chain triglycerides (MCT) for patients affected with disorders of long-chain FAO; - some specific supplementations (for example, L-carnitine). These strategies are often ineffective. The aim of the present study is to evaluate new therapeutic ways based on the underlying energetic defect observed in these disorders. The long-term goal is to develop efficient therapies of these disorders. |
NCT00947960 ↗ | Triheptanoin Treatment Trial for Patients With Adult Polyglucosan Body Disease | Completed | Ultragenyx Pharmaceutical Inc | Phase 2 | 2009-06-01 | The purpose of the study is to determine if triheptanoin is an effective treatment for the symptoms of Adult Polyglucosan Body Disease. |
NCT00947960 ↗ | Triheptanoin Treatment Trial for Patients With Adult Polyglucosan Body Disease | Completed | Baylor Research Institute | Phase 2 | 2009-06-01 | The purpose of the study is to determine if triheptanoin is an effective treatment for the symptoms of Adult Polyglucosan Body Disease. |
NCT00983788 ↗ | Effect of Bezafibrate on Muscle Metabolism in Patients With Fatty Acid Oxidation Defects | Completed | Groupe Hospitalier Pitie-Salpetriere | Phase 2 | 2009-10-01 | The investigators propose to evaluate the effect of bezafibrate on metabolism during exercise in 22 adult patients affected with carnitine palmitoyltransferase II (CPTII) or very-long chain acyl-CoA-dehydrogenase (VLCAD) deficiencies. This study will be an 9-month, randomized, double-blind, placebo-controlled crossover trial. The trial will be conducted in two centers: Institut de Myologie, Pitié-Salpêtrière Hospital in France, and Rigshospitalet, University of Copenhagen, in Denmark. The main criteria for assessing the potential effect of this drug will be the fat oxidation rate studied during a moderate workload on cycle ergometer, after infusion of stable isotopes (palmitate and glucose tracers). |
NCT00983788 ↗ | Effect of Bezafibrate on Muscle Metabolism in Patients With Fatty Acid Oxidation Defects | Completed | Rigshospitalet, Denmark | Phase 2 | 2009-10-01 | The investigators propose to evaluate the effect of bezafibrate on metabolism during exercise in 22 adult patients affected with carnitine palmitoyltransferase II (CPTII) or very-long chain acyl-CoA-dehydrogenase (VLCAD) deficiencies. This study will be an 9-month, randomized, double-blind, placebo-controlled crossover trial. The trial will be conducted in two centers: Institut de Myologie, Pitié-Salpêtrière Hospital in France, and Rigshospitalet, University of Copenhagen, in Denmark. The main criteria for assessing the potential effect of this drug will be the fat oxidation rate studied during a moderate workload on cycle ergometer, after infusion of stable isotopes (palmitate and glucose tracers). |
NCT01379625 ↗ | Study of Triheptanoin for Treatment of Long-Chain Fatty Acid Oxidation Disorder | Completed | University of Pittsburgh | Phase 2 | 2011-09-01 | Humans eat long-chain fat in their diet and use it for energy during exercise and during periods of fasting. Patients with long-chain fatty acid oxidation disorders cannot use dietary fat for energy. They sometimes develop muscle breakdown, and severe pain with exercise or illness. They can also develop a heart that does not function properly. These patients are tired and expend less energy than people who do not have a long-chain fatty acid oxidation disorder. However, they can use a supplement oil called medium chain triglyceride or MCT. This study will determine if a new experimental oil called Triheptanoin can decrease the muscle pain and increase the heart function and the amount of energy in patients with long-chain fatty acid oxidation disorders. Funding source - FDA's OOPD |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for triheptanoin
Condition Name
Clinical Trial Locations for triheptanoin
Trials by Country
Clinical Trial Progress for triheptanoin
Clinical Trial Phase
Clinical Trial Sponsors for triheptanoin
Sponsor Name
Sponsor Name for triheptanoin | |
Sponsor | Trials |
Ultragenyx Pharmaceutical Inc | 17 |
University of Texas Southwestern Medical Center | 5 |
Institut National de la Santé Et de la Recherche Médicale, France | 4 |
[disabled in preview] | 10 |
This preview shows a limited data set Subscribe for full access, or try a Trial |